Breyanzi
The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
| Name | Breyanzi |
|---|---|
| Active Substance | lizokaptagen maraleucel (genetički modificirane autologne stanice usmjerene protiv CD19 koje čine pročišćene CD8+ i CD4+ T-stanice) |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | ograničeni recept |
| Distribution | Supply through pharmacies (community) |
| ATC Code | L01XL08 |
| Summary of product characteristics (SmPC), labelling and package leaflet (PL) | download |
| Link to the European Medicines Agency's (EMA) product information | download |
| Link to the European Commission's (EC) decisions | download |
